Scarica l'app Stockscreener
0.466
19.31%
-0.1115
Dopo l'orario di chiusura:
.48
0.014
+3.00%
Precedente Chiudi:
$0.5775
Aprire:
$0.55
Volume 24 ore:
620.44K
Relative Volume:
3.39
Capitalizzazione di mercato:
$1.10M
Reddito:
Utile/perdita netta:
$-4.23M
Rapporto P/E:
-0.053
EPS:
-8.8
Flusso di cassa netto:
$-1.89M
1 W Prestazione:
-26.23%
1M Prestazione:
-77.27%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$0.4216
$0.58
Intervallo di 1 settimana:
$0.4216
$0.6669
Portata 52W:
$0.4216
$98.20
Lakewood Amedex Biotherapeutics Inc Stock (LABT) Company Profile
Nome
Lakewood Amedex Biotherapeutics Inc
Settore
Industria
Telefono
(941) 225-2515
Indirizzo
8031 COOPER CREEK BLVD., UNIVERSITY PARK
Compare LABT vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LABT
Lakewood Amedex Biotherapeutics Inc
|
0.466 | 1.10M | 0 | -4.23M | -1.89M | -8.80 |
VRTX
Vertex Pharmaceuticals Inc
|
524.52 | 132.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
245.81 | 98.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
805.67 | 82.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
890.05 | 55.97B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
386.46 | 43.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Lakewood Amedex Biotherapeutics Inc Borsa (LABT) Ultime notizie
Lakewood-Amedex Biotherapeutics Inc.Common Stock (Nasdaq:LABT) Stock Quote - FinancialContent
LABT Stock Whipsaws As Traders Focus On Cash And Volatility - Timothy Sykes
A topical candidate showed lab activity against drug-resistant bacteria from foot ulcers - Stock Titan
Is Lakewood-Amedex Biotherapeutics Inc. (LABT) Rewriting the Penny Stocks Playbook? - Kalkine Media
Lakewood-Amedex Biotherapeutics (LABT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
How Is Lakewood-Amedex (NASDAQ:LABT) Preparing Its Nu-3 Program for Midstage Testing? - Kalkine Media
Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter Highlighting Transformational Progress & Outlook for Nu-3 - The Columbus Dispatch
Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter Highlighting Transformational Progress & Outlook for Nu-3 - Akron Beacon Journal
Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead By Investing.com - Investing.com Canada
Before human trials, a wound gel killed drug-resistant bacteria without generating resistance - Stock Titan
Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead By Investing.com - Investing.com Australia
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 - PR Newswire
Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead - Investing.com
IPO Databook: Lakewood-Amedex Biotherapeutics (LABT US)Sep 2026 - Smartkarma
LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC
Lakewood-Amedex (NASDAQ: LABT) faces shareholder stock resale that brings it no cash - Stock Titan
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - openPR.com
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - Akron Beacon Journal
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - Democrat and Chronicle
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - azcentral.com and The Arizona Republic
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - Kitsap Sun
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The Tennessean
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The National Law Review
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - WBOC TV
Lakewood-Amedex CEO to present new antimicrobia... - Pluang
Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - PR Newswire
Investors and potential partners will meet a biotech CEO from Lakewood-Amedex Sept. 14–16 - Stock Titan
Biotech Pre-Market Movers: BIAF, LABT, ALMS, PASW Swing Big - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Trending Stocks Today | SONO Group Soars 81.34% Post-Market - Moomoo
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Lakewood-Amedex Biotherapeutics Company Profile & Introduction - Moomoo
Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company - markets.businessinsider.com
Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company - Yahoo Finance
Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ: LABT) Stock Price, News & Analysis - Kalkine
Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ: LABT) Stock Price, News & Analysis - kalkine.ca
Lakewood-Amedex Biotherapeutics (LABT) investor WFI Equity discloses 8.8% ownership stake - Stock Titan
Lakewood-Amedex raises $7.5M Series C, lists on Nasdaq and clears $1.5M debt - Dealroom
Lakewood-Amedex Raises $7.5M and Lists on NASDAQ, Shedding $1.5M Debt - Minichart
LABT: Q2 net loss rose sharply on higher R&D and G&A costs; liquidity improved after Series C financing - TradingView
Lakewood-Amedex Biotherapeutics Inc. Q2 2026: Revenue $0 Net loss $(3.90M), EPS $(2.75) — 10-Q Summary - TradingView
Lakewood-Amedex (NASDAQ: LABT) raises $7.5M, expands cash yet flags going concern - Stock Titan
Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Australia
Lakewood-Amedex Biotherapeutics announces annual shareholder meeting - Bitget
Lakewood-Amedex Biotherapeutics announces annual shareholder meeting - Bitget
Lakewood-Amedex (NASDAQ: LABT) seeks 100M share authorization and reverse split power - Stock Titan
Lindesfarne LLC reports 8.582% LABT stake in Lakewood-Amedex Biotherapeutics (LABT) filing - Stock Titan
Lakewood-Amedex Biotherapeutics (LABT) Earnings Date and Reports 2026 $LABT - MarketBeat
Lakewood-Amedex Biotherapeutics (LABT) asks investors to approve major share and reverse split powers - Stock Titan
Lakewood-Amedex Biotherapeutics Inc. Revenue Breakdown – NASDAQ:LABT - TradingView
Lakewood Amedex Biotherapeutics Inc Azioni (LABT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):